PRO 2000
- Generic Name
- PRO 2000
- Drug Type
- Small Molecule
- CAS Number
- 29321-75-3
- Background
PRO 2000 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials. It is being studied for the prevention of HIV infection and other sexually transmitted diseases. This medicine does not cure HIV infection or AIDS and is being studied to reduce the risk of passing the virus to other people.
- Indication
Investigated for use/treatment in HIV prevention, prevention of stdis, and vaginal infection.
BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2003-12-15
- Last Posted Date
- 2021-11-08
- Target Recruit Count
- 3101
- Registration Number
- NCT00074425
- Locations
- 🇲🇼
University of North Carolina Lilongwe CRS, Lilongwe, Central, Malawi
🇲🇼College of Med. JHU CRS, Blantyre, Southern, Malawi
🇿🇦Med. Research Council-Hlabisa, Durban, KwaZulu-Natal, South Africa
Safety and Tolerability of the Vaginal Gel PRO 2000/5
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-07-30
- Target Recruit Count
- 60
- Registration Number
- NCT00006207
- Locations
- 🇺🇸
Julia Welch, Research Triangle Park, North Carolina, United States
Effects of BufferGel and PRO 2000/5 Gel in Men
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 24
- Registration Number
- NCT00016536
- Locations
- 🇺🇸
UW HIV Prevention CRS, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.